The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessAbstract
Ann Oncol 2017; 28: iv119–iv142 (doi:10.1093/annonc/mdx225) Under the section “Gastrointestinal toxicity: Gastrointestinal toxicity of anti-CTLA4 antibodies: Diagnosis” The sigmoid colon and the rectum are involved in most cases; therefore, a flexible sigmoidoscopy is generally sufficient to make the diagnosis of anti-CTLA4-induced enterocolitis [38]. Is replaced with: The sigmoid colon and the rectum are involved in most cases; therefore, a flexible sigmoidoscopy is generally sufficient to make the diagnosis of anti-CTLA4-induced enterocolitis [38, 42]. Under the section “Gastrointestinal toxicity: Gastrointestinal toxicity of anti-CTLA4 antibodies: Management” Overall, one-third to two-thirds of patients either do not respond to high-dose i.v. steroids, or have a relapse requiring an increase in the corticosteroid dosage during the course of steroid tapering. These patients require infliximab and usually have an excellent response. A single dose of infliximab (5mg/kg) is generally sufficient [18, 35, 36, 38]. Is replaced with: Overall, one-third to two-thirds of patients either do not respond to high-dose i.v. steroids, or have a relapse requiring an increase in the corticosteroid dosage during the course of steroid tapering [38, 42]. These patients require infliximab and usually have an excellent response. A single dose of infliximab (5mg/kg) is generally sufficient [18, 35, 36, 38, 42]. Figures The following changes apply as shown in the updated version below. In “Figure 8. ICPi-related toxicity: management of diarrhoea and colitis” Mild (G1): i.e. < 3 liquid stools per day over baseline, feeling well ICPi can be continued Is replaced with: Mild (G1): i.e. < 4 liquid stools per day over baseline, feeling well ICPi can be continued Severe (G3/4): i.e. > 6 liquid stools per day over baseline or if episodes within 1h of eating Requires hospitalisation and isolation until infection excluded ICPi to be withheld Is replaced with: Severe (G3/4): i.e. ≥ 7 liquid stools per day or life-threatening Requires hospitalisation and isolation until infection excluded ICPi to be withheld Below “Figure 9. ICPi-related toxicity: management of pneumonitis” Ab, antibody; Is replaced with: Ab, antibiotic; Under the section “Acknowledgements” We thank Prof. M. Gore and Dr L. Spain from the Royal Marsden Hospital, London, UK, for their help with developing the up-to-date AE management algorithms. Is replaced with: We thank Prof. M. Gore and Dr L. Spain from the Royal Marsden Hospital, London, UK, for their help with developing the up-to-date AE management algorithms. Dr Spain provided the irAE management algorithms for this article. Under the section “References” A new reference is added: 42. Verschuren EC, van den Eertwegh AJ, Wonders J et al. Clinical, endoscopic and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol 2016; 14: 836–842. 49. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375–384. Is replaced with: 50. Weber JS, Gibney G, Sullivan RJ et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 2016; 17: 943–955. September 2018 When the above changes were made, Figure 6 was accidentally replaced with Figure 8 in the original article. This has now been corrected back. The Publisher apologizes for the error. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of OncologyVol. 28PreviewImmunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand PD-L1 has become standard of care for an increasing number of indications (Table 1). Therefore, an increasing number of patients will be exposed to these drugs with a chance of developing toxicities from these treatments. Depending on the immune checkpoint that is targeted, the incidence of toxicity varies. Toxicities from immune checkpoint inhibitors (ICPis) can be divided into infusion reactions and immune-related adverse events (irAEs) or adverse events of special interest (AEoSI). Full-Text PDF Open Archive
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, treatment for irAEs typically involves terminating ICB and initiating a course of high-dose corticosteroids”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Haanen et al., 2018
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
A review of cancer immunotherapy toxicity
Kennedy, L. B., & Salama, A. K. S. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,364
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Immune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982
Metadata
- Authors
- Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 29
- Pages
- iv264-iv266
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2999042597
- Cited by
- 431
- References
- 0
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 37 · 2023: 57 · 2022: 64 · 2021: 88 · 2020: 93 · 2019: 57 · 2018: 2
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 463 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- immunotherapy toxicity, immune checkpoint inhibitors, anti-CTLA-4 antibody, enterocolitis, gastrointestinal toxicity, infliximab, corticosteroids, diarrhea, colitis, immune-related adverse events, flexible sigmoidoscopy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. https://app.cochat.ai/papers/10.1093/annonc/mdy162
- The paper
- Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2018). Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. https://doi.org/10.1093/annonc/mdy162
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.